Jump to content

FT-104

Add links
From Wikipedia, the free encyclopedia

FT-104
Clinical data
Other namesRE-104; RE104; 4-glutaryloxy-N,N-diisopropyltryptamine
Legal status
Legal status
  • Investigational
Identifiers
  • 1-[3-[2-[Bis(1-methylethyl)amino]ethyl]-1H-indol-4-yl] pentanedioate
CAS Number
PubChem CID
Chemical and physical data
FormulaC21H30N2O
Molar mass326.484 g·mol−1
3D model (JSmol)
  • CC(C)N(CCC1=CNC2=C1C(=CC=C2)OC(=O)CCCC(=O)O)C(C)C
  • InChI=1S/C21H30N2O4/c1-14(2)23(15(3)4)12-11-16-13-22-17-7-5-8-18(21(16)17)27-20(26)10-6-9-19(24)25/h5,7-8,13-15,22H,6,9-12H2,1-4H3,(H,24,25)
  • Key:LSDOIAGGRBGDJJ-UHFFFAOYSA-N

FT-104 (also known as RE-104 and 4-glutaryloxy-N,N-diisopropyltryptamine) is a psychedelic tryptamine derivative which is a prodrug ester of the well known designer drug 4-HO-DiPT.[1] It is one of a number of related derivatives developed for potential medical applications, and is in human clinical trials as a possible treatment for postpartum depression and treatment-resistant depression.[2][3][4][5]

It is being developed by the pharmaceutical company Reunion Neuroscience.[6]  As of 2024, FT-104 is entering Phase II clinical trials for post-partum depression.[7]

Pharmacology

[edit]

FT-104 is a prodrug that is converted into the psychedelic tryptamine 4-HO-DiPT upon administration.[1][8]  4-OH-DiPT then acts as an agonist on the serotonin 2A receptor which leads to an antidepressant effect.[6]

See also

[edit]

References

[edit]
  1. ^ a b Bryson N, Alexander R, Asnis-Alibozek A, Ehlers MD (June 2024). "RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-N,N-diisopropyltryptamine". ACS Chemical Neuroscience. 15 (12): 2386–2395. doi:10.1021/acschemneuro.4c00058. PMC 11191588. PMID 38758589.
  2. ^ Hallifax J (11 August 2022). "An Inside Look into Field Trip's Next-Generation Psychedelic, FT-104".
  3. ^ WO 2022/000091, Bryson N, "Tryptamine prodrugs", published 6 January 2022, assigned to Field Trip Psychedelics Inc. 
  4. ^ US 2022/0024956, Slassi A, Araujo J, "Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders.", published 27 January 2022, assigned to Mindset Pharma Inc. 
  5. ^ WO 2022/246572, Slassi A, Araujo J, Higgin GH, Gabriele J, "Hallucinogen-Fatty Acid Combination", published 1 December 2022, assigned to Mindset Pharma Inc. 
  6. ^ a b Braner S (May 8, 2024). "Reunion Neuroscience raises $103 million for a psychedelic to treat depression". Chemical & Engineering News.
  7. ^ Alexander R, Hocevar-Trnka J (June 26, 2024). "RE104: A Novel, Fast-Acting Psychedelic for Postpartum Depression". psychiatrictimes.com.
  8. ^ "Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders". GlobalNewswire. May 20, 2024 – via Yahoo!Finance.
Retrieved from "https://en.wikipedia.org/w/index.php?title=FT-104&oldid=1254917434"